[Medulloblastoma: towards new prognostic factors].


Current therapeutic protocols for medulloblastoma combining, with surgery, radiation therapy and chemotherapy allow 5-year survival rates of over 50%. However these therapies induce mainly in children long-term adverse effects, which produce a therapeutic dilemma emphasizing the need for reliable prognostic factors in order to adapt the treatment modalities… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics